Abbott India Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast

Abbott India trades at Rs 27,640, roughly 25% below its 52-week high of Rs 37,000, while reporting FY26 EPS of Rs 730 and carrying virtually zero debt with a large cash pile. The puzzle most retail investors miss: what the market calls Abbott India is only the branded prescription formulations business. Medical devices, diagnostics, and nutrition, which form a large part of Abbott's real India franchise, sit entirely in unlisted Abbott Healthcare Pvt Ltd. ABBOTINDIA shareholders own a fraction of the overall Abbott India pie, yet the stock is priced at ~38x earnings as if they owned the full enterprise. The Abbott India share price target of Rs 30,810 for 2027, rising to Rs 45,640 by 2030, is priced off that sliced franchise, compounding at ~14% annually.

The second layer most investors miss: Abbott India periodically pays large special dividends funded by its cash balance, not just a regular annual payout. For long-term holders, the effective yield on an entry at current levels adds meaningfully to total return over the 2027 to 2030 window of the Abbott India share price target.

This article covers the Abbott India share price target 2027, 2028, and 2030 based on FY26 financials, analyst consensus, and scenario modelling as of July 2026.

Click Here – Get Free Investment Predictions

Abbott India Company Overview

Metric	Details
NSE Ticker	ABBOTINDIA
Sector	Pharma (Multinational Branded Generics)
CMP (15 Jul 2026)	Rs 27,640
52-Week High	Rs 37,000
52-Week Low	Rs 25,275
Market Cap	Rs 57,740 Cr
FY26 EPS	Rs 730.4 (~14% annual growth)
Trailing PE	~38x
12M Consensus Target	Rs 32,800 (+19%)
Abbott India Share Price Target 2027	Rs 30,810 (+11%)
Abbott India Share Price Target 2028	Rs 35,120 (+27%)
Abbott India Share Price Target 2030	Rs 45,640 (+65%)
Bull Case 2030	Rs 56,000
Bear Case 2030	Rs 36,500

What most screens miss: Abbott India carries zero net debt and a large cash balance, while Abbott Laboratories holds ~75% of the listed entity at the regulatory ceiling. The ~25% free float is structurally scarce, creating a liquidity premium that keeps the PE well above the earnings growth rate. Medical devices and diagnostics, which grow faster, remain entirely in unlisted Abbott Healthcare Pvt Ltd.

Abbott India Limited is the Indian subsidiary of Abbott Laboratories, USA, and has operated in India since 1944. The company markets branded prescription drugs, OTC health products, and medical nutrition products across India under brands including Digene, Duphaston, Thyronorm, and Cremaffin. The parent Abbott Laboratories holds ~75% of ABBOTINDIA at the maximum permissible promoter stake, leaving a thin ~25% free float that limits selling pressure and maintains the quality premium.

Why Is the Abbott India Share Price Target Set at Rs 30,810 for 2027

Branded Generics Are Structurally Defensive

Abbott India's formulations portfolio sits in established brands with decades of physician trust and chemist network penetration. Branded generics in India compete on physician preference and institutional relationships that generic manufacturers cannot easily replicate. This structural defensiveness means Abbott India's earnings compound with low volatility, a quality the market prices in via the premium multiple underpinning the Abbott India share price target.

Zero Debt and Large Cash Make Each Rupee of EPS High Quality

With virtually zero borrowings and a large cash and investment balance, Abbott India's reported EPS of Rs 730.4 carries no interest expense, no refinancing risk, and no dilution threat. The cash balance funds periodic special dividends and is available for opportunistic bolt-on acquisitions if the parent chooses to expand the listed entity's scope. This balance sheet quality is a pillar of the long-term Abbott India share price target from 2027 through 2030.

Consistent Earnings Compounding Through Price and Volume

Abbott India has delivered earnings compounding of ~14% annually through a combination of modest volume growth in its therapeutic areas (thyroid, gynaecology, gastroenterology) and annual price increases within NPPA ceiling limits. FY27 earnings recovery is expected to sustain this trajectory as institutional flows return to quality pharma names, supporting the 12-month analyst consensus of Rs 32,800 and the broader Abbott India share price target.

Promoter Holding Near Ceiling Creates Structural Float Scarcity

Abbott Laboratories holds ~75% of ABBOTINDIA at the maximum permissible limit under SEBI promoter holding rules. The ~25% free float means institutional demand for any incremental position moves the price more than it would for a widely held mid-cap. This structural scarcity premium is embedded in the PE multiple and provides a valuation floor for the Abbott India share price target thesis through 2030.

Periodic Special Dividends Enhance Total Return Significantly

Abbott India has a history of paying dividends well above its regular payout ratio when its cash pile accumulates. These periodic large special dividends are not captured in a standard dividend yield calculation but add meaningfully to total return over the Abbott India share price target 2030 window for long-term holders entered near current levels.

Abbott India Share Price Targets 2027, 2028 and 2030

Abbott India Share Price Target 2027: Rs 30,810

The Abbott India share price target 2027 is Rs 30,810, implying ~11% upside from CMP Rs 27,640. This modest near-term target reflects the stock already trading at a premium multiple, with the 2027 target essentially a 1-year earnings growth pass-through at ~36x forward FY28 EPS of ~Rs 855. The key catalyst for 2027 is sustained FY27 earnings delivery and any re-rating as FII flows return to quality pharma stocks.

Abbott India Share Price Target 2028: Rs 35,120

The Abbott India share price target 2028 is Rs 35,120, implying ~27% upside from CMP. FY29 EPS of ~Rs 975 at a forward multiple of ~36x drives this target. By 2028, two full years of post-correction earnings compounding validate the premium multiple and close the gap between CMP and the fair value embedded in the 2028 target.

Abbott India Share Price Target 2030: Rs 45,640

The Abbott India share price target 2030 is Rs 45,640, implying ~65% upside and a 4-year CAGR of ~13% from current levels. FY31 EPS of ~Rs 1,390 at a forward multiple of ~33x, slightly moderated from today's 38x, supports this target. By 2030, Abbott India should have compounded through multiple NPPA price revision cycles with its brand premiums intact and its special dividend track record reinforcing the quality-compounder thesis.

Bull Case and Bear Case for the Abbott India Share Price Target 2030

Bull Case: Rs 56,000

The bull case Abbott India share price target of Rs 56,000 by 2030 assumes 17% EPS compounding through FY31, driven by premiumisation in chronic therapy areas, OTC health product penetration, and any expansion of the listed entity's scope to include additional product lines from the Abbott global portfolio. A re-rating of the PE to 40x as the quality premium widens would compound the EPS-driven upside. This scenario requires both earnings acceleration and market willingness to pay above-historical multiples.

Bear Case: Rs 36,500

The bear case Abbott India share price target of Rs 36,500 by 2030 applies if NPPA price controls intensify, volume growth decelerates, and the market re-rates the stock toward 27x as sentiment shifts to value-oriented pharma. FY31 EPS of ~Rs 1,050 at 27x multiple represents a scenario where Abbott India delivers earnings but receives a lower premium. Even in this scenario, the downside from CMP is limited by the cash-backed balance sheet.

Scenario	Target by 2030	Return from CMP	Key Assumption
Bull Case	Rs 56,000	+103%	17% EPS CAGR; PE stays at 40x; product scope expansion
Base Case	Rs 45,640	+65%	14% EPS CAGR; PE moderates to 33x; steady compounder
Bear Case	Rs 36,500	+32%	9% EPS CAGR; PE compresses to 27x; NPPA headwinds

Key Risks to the Abbott India Share Price Target

NPPA Price Control Risk

Abbott India sells branded prescription drugs subject to price ceilings enforced by the National Pharmaceutical Pricing Authority. Any expansion of drugs under price control, or a reduction in the ceiling for existing Abbott products, would compress revenue and EPS, reducing the earnings base that the Abbott India share price target rests on.

Unlisted Franchise Overhang

Abbott Laboratories could restructure its India operations in ways that reduce the listed entity's product scope, reducing the franchise investors are paying for at the current premium multiple. Any uncertainty around the boundary between listed and unlisted operations is a specific risk to this stock.

Premium Multiple De-Rating Risk

At ~38x trailing earnings, Abbott India is priced for consistent execution. Any earnings miss, even a single quarter, can trigger a sharp de-rating given that the multiple leaves little room for disappointment. A deterioration of FII flows from quality pharma could compress the PE toward 28 to 30x, affecting the Abbott India share price target timeline.

FII Selling Pressure

Foreign institutional investors hold a meaningful portion of the ~25% free float. Any broad emerging market risk-off event or India-specific FII outflow cycle could reduce institutional demand and pressure the Abbott India share price target timeline independent of the underlying business performance.

How to Invest in Abbott India

Begin with fundamentals by tracking Abbott India's quarterly earnings releases and any NPPA circulars covering its key therapeutic areas. The Univest Screener lets you monitor live PE levels, analyst targets, and price alerts for ABBOTINDIA alongside the broader pharma sector. To purchase shares, open a demat account with any SEBI-registered broker and search NSE ticker ABBOTINDIA. Given the high per-share price, consider systematic purchases across two to three tranches rather than a single lump sum. Monitor the annual dividend announcement as a data point on cash utilisation. Consult a SEBI-registered financial advisor before making any investment decision.

Use the Univest Screener to Track Abbott India Live Fundamentals and Analyst Targets

Conclusion

The Abbott India share price target of Rs 30,810 for 2027, Rs 35,120 for 2028, and Rs 45,640 for 2030 reflects a quality-compounder thesis anchored in branded prescription drugs, a zero-debt balance sheet, periodic special dividends, and a structurally thin free float. The near-term upside is modest because the premium multiple already captures much of the short-term outlook. The compounding case plays out over three to four years as EPS grows from Rs 730 toward Rs 1,390 by FY31. The most important variable to track: whether NPPA price controls expand materially into Abbott India's core therapy areas of thyroid, gynaecology, and gastroenterology.

Download the Univest iOS App or Univest Android App to track Abbott India live price and get daily stock recommendations.

Frequently Asked Questions on Abbott India Share Price Target 2027 2028 and 2030

What is the Abbott India share price target for 2027?

Ans. The Abbott India share price target for 2027 is Rs 30,810, representing ~11% upside from CMP Rs 27,640 as of July 2026. This assumes FY28 EPS of ~Rs 855 capitalised at ~36x. The larger compounding plays out in 2028 (Rs 35,120, +27%) and 2030 (Rs 45,640, +65%). Verify latest data at NSE before investing.

What is the Abbott India share price target for 2030?

Ans. The Abbott India share price target for 2030 is Rs 45,640, implying ~65% upside from CMP Rs 27,640. This is based on FY31 EPS of ~Rs 1,390 at a forward multiple of ~33x, assuming ~14% annual earnings compounding tapering to ~11%. These are analyst estimates, not guaranteed returns.

Why does Abbott India trade at such a high PE multiple?

Ans. Abbott India trades at ~38x trailing earnings because it offers near-zero business risk: zero debt, large cash reserves, a multinational parent with deep branded formulations, and a history of periodic large special dividends. The premium reflects quality and predictability rather than growth optionality. Investors should assess whether that premium is justified relative to domestic pharma peers.

What most investors miss about Abbott India?

Ans. The listed entity sells only Abbott's branded prescription formulations. Abbott's medical devices, diagnostics, and nutrition businesses in India operate entirely through unlisted Abbott Healthcare Pvt Ltd. ABBOTINDIA shareholders therefore own only a fraction of Abbott's actual India business, though the formulations business itself is high-margin and consistently cash-generative.

What is the bull case for the Abbott India share price target 2030?

Ans. The bull case Abbott India share price target for 2030 is Rs 56,000, assuming 17% EPS compounding through FY31 as the company accelerates premiumisation in branded generics and gains further traction in OTC health products. A multiple re-rating to 40x as the quality premium widens would drive this outcome. These are projections, not guaranteed returns.

What are the key risks to the Abbott India share price target?

Ans. Key risks include government price control interventions under NPPA reducing branded formulation pricing, any change in Abbott Laboratories' India strategy affecting the listed entity's product scope, FII selling pressure given the rich valuation, and competition from domestic generic manufacturers in key therapy areas.

What is Abbott India's 52-week high and low share price?

Ans. Abbott India's 52-week high is Rs 37,000 and the 52-week low is Rs 25,275 as of July 2026. The CMP of Rs 27,640 is ~25% below the 52-week high, representing a meaningful correction from peak levels. Verify the latest range at NSE India before making any investment decision.

How can I buy Abbott India shares?

Ans. You can buy Abbott India shares through any SEBI-registered broker by searching for NSE ticker ABBOTINDIA. Given the high per-share price (~Rs 27,640), the position size will be smaller in share terms. Review quarterly earnings and any NPPA price control developments before investing. Consult a SEBI-registered financial advisor for personalised guidance.